{"id":"dhea-and-acolbifene","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal bleeding or spotting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"}]},"_chembl":{"chemblId":"CHEMBL2105965","moleculeType":"Small molecule","molecularWeight":"494.03"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DHEA (dehydroepiandrosterone) is a prohormone that can be converted to estrogen and testosterone in peripheral tissues. Acolbifene is a selective estrogen receptor modulator that preferentially activates estrogen receptors in bone and vaginal tissue while avoiding activation in breast and endometrial tissue. Together, they aim to address menopausal symptoms and vaginal atrophy with a favorable safety profile.","oneSentence":"DHEA and acolbifene work together as a selective estrogen receptor modulator (SERM) combination to provide estrogen-like benefits in bone and vaginal tissue while minimizing systemic estrogen exposure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:25.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe vasomotor symptoms associated with menopause"},{"name":"Vaginal atrophy and genitourinary syndrome of menopause"}]},"trialDetails":[{"nctId":"NCT01452373","phase":"PHASE3","title":"Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2011-10","conditions":"Vasomotor Symptoms, Hot Flushes","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prasterone; dehydroepiandrosterone; EM-652.HCl"],"phase":"phase_3","status":"active","brandName":"DHEA and Acolbifene","genericName":"DHEA and Acolbifene","companyName":"EndoCeutics Inc.","companyId":"endoceutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DHEA and acolbifene work together as a selective estrogen receptor modulator (SERM) combination to provide estrogen-like benefits in bone and vaginal tissue while minimizing systemic estrogen exposure. Used for Moderate to severe vasomotor symptoms associated with menopause, Vaginal atrophy and genitourinary syndrome of menopause.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}